Cenix and Bayer, Molecula, Galapagos and Bayer, SMi Group, and Isis | GenomeWeb

Cenix Inks RNAi-Based Target Identification, Validation Deal with Bayer

Cenix BioScience said this week that it has signed a deal to use its genome-wide siRNA library to help Bayer HealthCare screen all known human druggable genes in an effort to identify and validate new drug targets.

Cenix said that, using cell-based assays developed in partnership with Bayer researchers, it expects to screen more than 6,000 genes in less than nine months.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.